Associate Editor

Thomas Martin, MD

Associate Editor

Dr. Martin is Clinical Research Director of Hematologic Malignancies at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.

Articles by Thomas Martin, MD

Thomas Martin, MDVideo Insights | September 19, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
View More
Sagar Lonial, MD, FACPPrint | August 17, 2023
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Thomas Martin, MDMeeting News | June 12, 2023
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | April 27, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | April 27, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | April 26, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | April 26, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | April 25, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | April 24, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Thomas Martin, MDViewpoints | April 10, 2023
We will all experience burnout at some point, and we all need to seek more personalized ways to cope.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Elias Jabbour, MDViewpoints | January 3, 2023
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 14, 2022
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
Thomas Martin, MDMyeloma | October 13, 2022
We are entering the great era of immunotherapy in multiple myeloma.